<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609334</url>
  </required_header>
  <id_info>
    <org_study_id>RSPR-007</org_study_id>
    <nct_id>NCT02609334</nct_id>
  </id_info>
  <brief_title>RSPR-007 Mannitol Challenge Trial</brief_title>
  <official_title>A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RSPR Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RSPR Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomised, placebo-controlled, cross-over, Phase 2 trial evaluating
      two doses (a low and a high) of CRD007 for the treatment of asthmatic trial subjects with a
      positive asthma test (mannitol challenge) prior to enrolment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present trial will include subjects with diagnosed asthma in a provocation model which
      mimics assessments of asthma control. Mannitol challenge is an indirect asthma provocation
      test, which requires the presence of inflammatory cells, particularly mast cells, in the
      airways.

      The trial involved in total 5 subject visits and will last for a maximum of 30 days for each
      subject from Visit 2 (Randomisation) to Visit 5 (Follow up).

      Visit 2,3, and 4 will be treatment visits where Investigational Medicinal Product (IMP) is
      administrated 3 hours before the Mannitol challenge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PD15 for mannitol after treatment with CRD007 and placebo</measure>
    <time_frame>Forced expiratory volume at one second (FEV1) manoeuvres are performed 60 seconds after each dose</time_frame>
    <description>The FEV1 value taken after the 0 mg capsule is taken as pre-challenge FEV1 and used to calculate the percentage decrease in FEV1 in response to the mannitol challenge. The test ends when the FEV1 has fallen by 15% or more (PD15)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tables are given as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRD007 Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Low dose&quot; of CRD007 (pemirolast sodium) given as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRD007 High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;High dose&quot; CRD007 (pemirolast sodium) given as a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRD007</intervention_name>
    <description>One single dose given 3 hours prior to Mannitol challenge</description>
    <arm_group_label>CRD007 Low dose</arm_group_label>
    <arm_group_label>CRD007 High dose</arm_group_label>
    <other_name>Pemirolast sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One single dose given 3 hours prior to Mannitol challenge</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥18 and &lt;50 years

          -  Diagnosis of asthma

        Exclusion Criteria:

          -  Clinical significant comorbidities

          -  Lower respiratory tract infection &lt;6 weeks prior to Visit 1

          -  Others, as specified in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vibeke Backer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bisbebjerg Hospital</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Pemirolast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

